Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

RCT (n=184) found no difference in renal response rate, or very good partial response rate between bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide in patients with initial myeloma cast nephropathy not requiring dialysis.


Journal of Clinical Oncology